Pancreatic Cancer Research

Clinical trialPhase 1Withdrawn

Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma

Outcome
Stopped earlyInsufficient accrual rate (Enrollment)
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Planned start
23 December 2019
Planned end
4 May 2021
Enrollment
0 participants
Sites
1
Primary outcomes
Completion Rate of oxaliplatin PEDD-PRVI; Safety of oxaliplatin PEDD-PRVI: maximum tolerable dose (MTD)
Sponsor type
Academic / other
Results posted
No
Last update
1 June 2021

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an open label, single institution, dose-escalation phase 1 study designed to assess the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde Venous Infusion (PRVI) using Pressure Enabled Drug Delivery (PEDD) technology. Oxaliplatin PEDD-PRVI is administered with systemic FOLFIRI followed by FOLFIRINOX therapy for the treatment of patients with unresectable or metastatic pancreatic adenocarcinoma.

Detailed description public domain (ClinicalTrials.gov)

The treatment period consists of 6 cycles. Cycles 1 and 2 involve the regional administration of oxaliplatin via PEDD-PRVI with systemic FOLFIRI. During cycles 1 and 2, patients are evaluated on days 1, 2, 4, and 8. Cycles 3 through 6 include the systemic administration of standard of care FOLFIRINOX. During cycles 3 through 6, patients are evaluated on days 1 and 8.